title: Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study.
abstract: OBJECTIVE
  Chemical defunctionalization of C-fiber bladder afferents with intravesical vanilloids such as capsaicin (CAP) or resiniferatoxin (RTX) improves detrusor hyperreflexia in humans and animals. The little existing data comparing the efficacy and tolerance of these 2 vanilloid agents seem to favor RTX in 10% alcohol over CAP, which is usually diluted in 30% alcohol. We compared the efficacy and tolerability of the 2 vanilloid agonists in what to our knowledge is the first randomized, controlled study comparing nonalcohol CAP vs RTX in 10% alcohol in neurogenic patients with detrusor hyperreflexia.
  
  
  METHODS
  This single center, randomized, double-blind, parallel groups study included 39 spinal cord injured adults with detrusor hyperreflexia. On day 0 patients were randomized to receive 1, 100 ml intravesical instillation of 100 nMol/l RTX diluted in 10% ethanol or 1 mmol/l CAP diluted in glucidic solvent. Efficacy (voiding chart and cystomanometry) and tolerability were evaluated during a 3-month followup.
  
  
  RESULTS
  On day 30 clinical and urodynamical improvement was found in 78% and 83% of patients with CAP vs 80% and 60% with RTX, respectively, without a significant difference between the 2 treated groups. The benefit remained in two-thirds of the 2 groups on day 90. There were no significant differences in regard to the incidence, nature or duration of side effects in CAP vs RTX treated patients.
  
  
  CONCLUSIONS
  Our results strongly argue for the importance of accounting for the role of vanilloid solute when interpreting the efficacy and tolerance of vesical vanilloid instillation in detrusor hyperreflexia cases. They suggest that a glucidic solute is a valuable solvent for vanilloid instillation.
authors.affiliation: Department ofPhysical Medicine and Rehabilitation, Bordeaux University Hospital, France. madeseze@club-internet.fr
authors.forename: Marianne
authors.initials: M
authors.lastname: de Sèze
authors.forename: Laurent
authors.initials: L
authors.lastname: Wiart
authors.forename: Mathieu-Panchoa
authors.initials: MP
authors.lastname: de Sèze
authors.forename: Luc
authors.initials: L
authors.lastname: Soyeur
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Dosque
authors.forename: Sylvie
authors.initials: S
authors.lastname: Blajezewski
authors.forename: Nicholas
authors.initials: N
authors.lastname: Moore
authors.forename: Bruno
authors.initials: B
authors.lastname: Brochet
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Mazaux
authors.forename: Michel
authors.initials: M
authors.lastname: Barat
authors.forename: Pierre-Alain
authors.initials: PA
authors.lastname: Joseph
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D002211:Capsaicin / Q000008:administration & dosage*; D004224:Diterpenes / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009498:Neurotoxins / Q000008:administration & dosage*; D012021:Reflex, Abnormal; D013119:Spinal Cord Injuries / Q000150:complications*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D004224:Diterpenes; D009498:Neurotoxins; C024353:resiniferatoxin; D002211:Capsaicin